Soluble heparin-binding EGF-like growth factor (HB-EGF) detected by newly developed immuno-PCR method is a clear-cut serological biomarker for ovarian cancer.
Soluble heparin-binding EGF-like growth factor (HB-EGF) detected by newly developed immuno-PCR method is a clear-cut serological biomarker for ovarian cancer.
复制标题
DOI：
--
复制
发表时间：
2012
影响因子：
2.2
通讯作者：
N. Kasai;Kazuhiro Kobayashi;Shinobu Shioya;Y. Yoshikawa;Fusanori Yotsumoto;S. Miyamoto;E. Mekada;J. Enokizono
中科院分区：
文献类型：
--
作者：
N. Kasai;Kazuhiro Kobayashi;Shinobu Shioya;Y. Yoshikawa;Fusanori Yotsumoto;S. Miyamoto;E. Mekada;J. Enokizono
肝素结合 EGF 样生长因子 (HB-EGF) 是 EGF 生长因子家族的成员，可结合并激活 EGF 受体。 HB-EGF 被合成为膜锚定蛋白 (proHB-EGF)，然后通过蛋白水解裂解，形成具有促有丝分裂活性的可溶形式。 HB-EGF 在发育和细胞增殖等病理生理过程中发挥着关键作用。在本研究中，我们开发了一种免疫 PCR 系统，用于测定人血清中可溶性 HB-EGF 浓度。利用对 HB-EGF 具有中和活性的单克隆抗体作为捕获抗体，可以提高对血清中活性形式 HB-EGF 的选择性，并且与现有方法相比，免疫 PCR 系统提高了其灵敏度。对20名卵巢癌患者和20名健康志愿者的HB-EGF测量结果显示，卵巢癌患者的HB-EGF浓度显着高于健康志愿者（P<0.05），这表明新开发的免疫PCR系统检测到的可溶性HB-EGF可以作为有用的血清学生物标志物，例如卵巢癌的诊断生物标志物，以及正在开发的抗HB-EGF靶向治疗的预测和药效生物标志物。
Heparin-binding EGF-like growth factor (HB-EGF) is a member of the EGF family of growth factors that bind to and activate the EGF receptor. HB-EGF is synthesized as a membrane-anchored protein (proHB-EGF), and then proteolytically cleaved, resulting in the mitogenically active soluble form. HB-EGF plays pivotal roles in pathophysiological processes such as development and cell proliferation. In this study, we developed an immuno-PCR system for the determination of soluble HB-EGF concentrations in human serum. Utilizing a monoclonal antibody with neutralizing activity against HB-EGF as a capture antibody resulted in increasing selectivity for an active form of HB-EGF in serum, and immuno-PCR system improved its sensitivity compared to the currently available methods. As a result of measurement of HB-EGF in 20 ovarian cancer patients and 20 healthy volunteers, ovarian cancer patients showed significantly higher concentrations than healthy volunteers (P< 0.05), which indicates that soluble HB-EGF detected by newly developed immuno-PCR system can be useful serological biomarkers such as a diagnostic biomarker for ovarian cancer, and a predictive and pharmacodynamic biomarker for anti-HB-EGF targeted therapies under development.